Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Completed · Phase 3 · Has a placebo group

Conditions studied: Relapsing-Remitting Multiple Sclerosis

In brief

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.

Key facts

Study ID
NCT00420212
Run by
Biogen
People needed
1234
Starts
2007-01-01
Expected to finish
2011-02-01
Last updated by the study team
2015-01-26

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.